GeoVax Labs (GOVX, Financial) has been reaffirmed with a Buy rating by Roth Capital analyst Jonathan Aschoff, who also maintained a price target of $20. This positive outlook follows comments by U.S. Health and Human Services Secretary Robert F. Kennedy Jr. regarding the limited effectiveness of monovalent vaccines against respiratory viruses due to their high mutation rates. Consequently, the FDA is now giving preference to the development of polyvalent vaccines.
This strategic shift in vaccine prioritization positions GeoVax favorably, particularly with its polyvalent COVID-19 vaccine, GEO-CM04S1. This vaccine recently secured significant financial backing from the Biomedical Advanced Research and Development Authority (BARDA) for a substantial 10,000-participant Phase 2 clinical trial.
Further bolstering GeoVax's prospects, early trials have shown that GEO-CM04S1 is outperforming current mRNA COVID-19 vaccines in smaller-scale studies. This development highlights GeoVax's potential to emerge as a key player in the evolving landscape of vaccine technology.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 5 analysts, the average target price for Geovax Labs Inc (GOVX, Financial) is $14.60 with a high estimate of $20.00 and a low estimate of $8.00. The average target implies an upside of 1,421.63% from the current price of $0.96. More detailed estimate data can be found on the Geovax Labs Inc (GOVX) Forecast page.
Based on the consensus recommendation from 5 brokerage firms, Geovax Labs Inc's (GOVX, Financial) average brokerage recommendation is currently 2.0, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
